Brief: Ultragenyx Completes Rolling Submission Of Biologics License Application To U.S. FDA For Dtx401 Aav Gene Therapy
30/12/2025 22:34
Dec 30 (Reuters) - Ultragenyx Pharmaceutical Inc RARE.O: ULTRAGENYX COMPLETES ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION (BLA) TO U.S. FDA FOR DTX401 AAV GENE THERAPY FOR GLYCOGEN STORAGE DISEASE TYPE IA (GSDIA) Source text: ID:nGNX91VnYD Further company coverage: RARE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ultragenyx Pharmaceutical
See all newsBrief: Ultragenyx Pharmaceutical Enters Settlement Agreement With Navinta On Dojolvi Patent Litigation - SEC Filing
Ultragenyx gains on $210 million US FDA voucher sale
Brief: Ultragenyx Pharmaceutical - Under Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih
Brief: Ultragenyx Enters Into Agreement To Sell Rare Pediatric Disease Priority Review Voucher For $210 Million
U.S. STOCKS ON THE MOVE-CoreWeave, StubHub, Ultragenyx